Efficacy, Safety, and Immunogenicity of Subcutaneous DMB-3115 Versus Stelara® in Patients With Moderate to Severe Chronic Plaque Psoriasis

• Status: Recruiting
• Trial end date: 2022-11-01
• Target enrollment: 0
• Participant gender: All

Summary

This study is designed to evaluate efficacy, safety, pharmacokinetics (PK) and immunogenicity of subcutaneously administered DMB-3115 in comparison with Stelara for treatment of moderate to severe chronic plaque psoriasis.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Dong-A ST Co., Ltd.
• Collaborator: Meiji Seika Pharma Co., Ltd.
• Treatments: Ustekinumab

Criteria

Inclusion Criteria:

• Patients who have a diagnosis of plaque-type psoriasis for at least 6 months.

Exclusion Criteria:

• Patients with hypersensitivity to ustekinumab or any of the product excipients.